358 related articles for article (PubMed ID: 32298469)
41. Updates in the Diagnosis and Management of AL Amyloidosis.
Cook J; Muchtar E; Warsame R
Curr Hematol Malig Rep; 2020 Jun; 15(3):155-167. PubMed ID: 32394186
[TBL] [Abstract][Full Text] [Related]
42. Use of novel therapies in the treatment of light chain amyloidosis.
Varga C; Titus SE; Toskic D; Comenzo RL
Blood Rev; 2019 Sep; 37():100581. PubMed ID: 31167719
[TBL] [Abstract][Full Text] [Related]
43. Daratumumab for relapsed or refractory AL amyloidosis with high plasma cell burden.
Schwotzer R; Manz MG; Pederiva S; Waibel C; Caspar C; Lerch E; Flammer AJ; Brouwers S; Seeger H; Heimgartner R; Fehr T; Rossi D; Bianchi E; Stüssi G; Ghilardi G; Gerber B
Hematol Oncol; 2019 Dec; 37(5):595-600. PubMed ID: 31486522
[TBL] [Abstract][Full Text] [Related]
44. Immunoglobulin Light Chain Systemic Amyloidosis.
Dispenzieri A; Merlini G
Cancer Treat Res; 2016; 169():273-318. PubMed ID: 27696268
[TBL] [Abstract][Full Text] [Related]
45. Role of autologous haematopoietic cell transplantation in the treatment of systemic light chain amyloidosis in the era of anti-CD38 monoclonal antibodies.
Chakraborty R; Milani P; Palladini G; Gertz M
Lancet Haematol; 2023 Nov; 10(11):e936-e940. PubMed ID: 37802087
[TBL] [Abstract][Full Text] [Related]
46. [Complete remission of nephrotic syndrome and improvement of renal function in a patient with light chain deposition disease following high dose chemotherapy with transplantation of autologous haematopoietic stem cells. A case study and review of literature].
Adam Z; Krejcí M; Pour L; Stepánková S; Cermáková Z; Voska L; Teplan V; Krivanová A; Hájek R; Mayer J
Vnitr Lek; 2009 Nov; 55(11):1089-96. PubMed ID: 20017442
[TBL] [Abstract][Full Text] [Related]
47. AL amyloidosis with a localized B cell neoplasia.
Stuhlmann-Laeisz C; Schönland SO; Hegenbart U; Oschlies I; Baumgart JV; Krüger S; Röcken C
Virchows Arch; 2019 Mar; 474(3):353-363. PubMed ID: 30680453
[TBL] [Abstract][Full Text] [Related]
48. High-Dose Melphalan and Autologous Peripheral Blood Stem Cell Transplantation in AL Amyloidosis.
Sanchorawala V
Acta Haematol; 2020; 143(4):381-387. PubMed ID: 32248194
[TBL] [Abstract][Full Text] [Related]
49. Bispecific Antibody (bsAb) Construct Formats and their Application in Cancer Therapy.
Acheampong DO
Protein Pept Lett; 2019; 26(7):479-493. PubMed ID: 30864494
[TBL] [Abstract][Full Text] [Related]
50. First report of CART treatment in AL amyloidosis and relapsed/refractory multiple myeloma.
Oliver-Caldes A; Jiménez R; Español-Rego M; Cibeira MT; Ortiz-Maldonado V; Quintana LF; Castillo P; Guijarro F; Tovar N; Montoro M; Benitez-Ribas D; Bataller A; González-Navarro EA; Cid J; Lozano M; Perez-Amill L; Martin-Antonio B; Mena MP; Moreno DF; Rodríguez-Lobato LG; Campistol JM; Calvo G; Bladé J; Rosiñol L; Juan M; Pascal M; Urbano-Ispizua A; Fernández de Larrea C
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34876408
[TBL] [Abstract][Full Text] [Related]
51. AL Amyloidosis: Current Chemotherapy and Immune Therapy Treatment Strategies:
Bianchi G; Zhang Y; Comenzo RL
JACC CardioOncol; 2021 Oct; 3(4):467-487. PubMed ID: 34729520
[TBL] [Abstract][Full Text] [Related]
52. Options for Chemotherapy and Scoring Response and Relapse.
Varga C; Chaulagain C
Hematol Oncol Clin North Am; 2020 Dec; 34(6):1115-1131. PubMed ID: 33099428
[TBL] [Abstract][Full Text] [Related]
53. Transcriptional heterogeneity of clonal plasma cells and immune evasion in immunoglobulin light chain amyloidosis.
Wang Y; Xu L; Liu Y; Hu Y; Shi Q; Jin L; Yang L; Wang P; Zhang K; Huang X; Ge Q; Lu J
Int J Hematol; 2021 Feb; 113(2):231-242. PubMed ID: 33040275
[TBL] [Abstract][Full Text] [Related]
54. Antibody treatment in multiple myeloma.
Maples KT; Johnson C; Lonial S
Clin Adv Hematol Oncol; 2021 Mar; 19(3):166-174. PubMed ID: 33739965
[TBL] [Abstract][Full Text] [Related]
55. Dawn of a new era of antibody-drug conjugates and bispecific T-cell engagers for treatment of multiple myeloma: a systematic review of literature.
Khattak ZE; Hashmi H; Khan SI; Aamir S; Arif U; Khan AI; Darwin A; Singh AD; Khouri J; Anwer F
Ann Hematol; 2021 Sep; 100(9):2155-2172. PubMed ID: 34318356
[TBL] [Abstract][Full Text] [Related]
56. [Immunoglobulin light chain amyloidosis: recent molecular, clinical and therapeutic approach].
Thierry A; Bridoux F; Goodman H; Belmouaz S; Abou Ayache R; Desport E; Jaccard A; Touchard G
Nephrologie; 2004; 25(4):111-8. PubMed ID: 15291138
[TBL] [Abstract][Full Text] [Related]
57. Recent advances in the management of AL Amyloidosis.
Kastritis E; Dimopoulos MA
Br J Haematol; 2016 Jan; 172(2):170-86. PubMed ID: 26491974
[TBL] [Abstract][Full Text] [Related]
58. Hepatic AL Amyloidosis without Significant Light Chain Elevation in a Patient Treated with CyBorD Plus Daratumumab.
Rybinski B; Kocoglu M
Am J Case Rep; 2021 Aug; 22():e933241. PubMed ID: 34421115
[TBL] [Abstract][Full Text] [Related]
59. Daratumumab, pomalidomide, and dexamethasone as a bridging therapy to autologous stem cell transplantation in a case of systemic light-chain amyloidosis with advanced cardiac involvement.
Arnall JR; Usmani SZ; Adamu H; Mishkin J; Bhutani M
J Oncol Pharm Pract; 2019 Jun; 25(4):1021-1025. PubMed ID: 30477388
[TBL] [Abstract][Full Text] [Related]
60. Amyloidogenic light chains impair plasma cell survival.
Pick M; Lebel E; Elgavish S; Benyamini H; Nevo Y; Hertz R; Bar-Tana J; Rognoni P; Merlini G; Gatt ME
Haematologica; 2023 Dec; 108(12):3359-3371. PubMed ID: 37381778
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
